1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) (RFA-DA-25-048) is sponsored by National Institute on Drug Abuse (NIDA). This funding opportunity supports small business concerns to develop technologies for commercialization that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42, R43/R44 Clinical Trial Optional) | Research Funding National Institutes of Health Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42, R43/R44 Clinical Trial Optional) The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBCs) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder.
Companion FOA: RFA-DA-25-048 , R43 / R44 Small Business Innovation Research Grants (SBIR) - Phase I/ Small Business Innovation Research Grants (SBIR) - Phase II Letter of Intent Due Date(s): 30 days prior to application due date Application Due Dates: March 13, 2024; March 13, 2025; RFA-DA-25-047 Expiration Date New Date November 17, 2025 per issuance of NOT-OD-26-006 Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
For the STTR program, the PD(s)/PI(s) may be employed with the SBC or the single, “partnering” non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC, which is characterized by an official relationship between the SBC and that individual.
Each PD/PI must commit a minimum of 10% effort to the project and the PD/PI must have a formal appointment with or commitment to the applicant small business concern, which is characterized by an official relationship between the small business concern and that individual. Such a relationship does not necessarily involve a salary or other form of remuneration.
Budgets up to $295,924 total costs per year for Phase I and up to $1,972,828 total costs per year for Phase II may be requested. Please refer to current Omnibus hard cap levels for FY25 and FY26 applications. These limits are subject to change each year.
Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
The current listing shows not specified, but for NIDA SBIR/STTR, budgets up to $306,872 total costs for Phase I and up to $2,045,816 total costs for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) (RFA-DA-25-048) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article